title: First clinical study of the selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache.
abstract: Granisetron (BRL 43694), a selective 5-HT3 receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but 1 patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.
authors.affiliation: Princess Margaret Migraine Clinic, Charing Cross Hospital, London, United Kingdom.
authors.forename: E G
authors.initials: EG
authors.lastname: Couturier
authors.forename: R
authors.initials: R
authors.lastname: Hering
authors.forename: C A
authors.initials: CA
authors.lastname: Foster
authors.forename: T J
authors.initials: TJ
authors.lastname: Steiner
authors.forename: F
authors.initials: F
authors.lastname: Clifford Rose
mesh_terms: D000328:Adult; D017829:Granisetron; D006801:Humans; D007191:Indazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D017829:Granisetron; D007191:Indazoles; D012702:Serotonin Antagonists